ArticleBMC cancer2026
SLC39A6 as a pan-cancer promising biomarker and actionable therapeutic target for CH5132799 sensitivity.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe zinc transporter SLC39A6, a member of the ZIP (Zrt-Irt-like protein) family, mediates zinc influx from the extracellular milieu into the cytosol and is indispensable for the function of numerous enzymes, transcription factors and signaling molecules. Previous studies have shown that SLC39A6 expression is associated with prognosis in esophageal squamous cell carcinoma and cervical cancer, indicating its potential impact on patient survival and tumor immunity. But a comprehensive pan-cancer analysis of SLC39A6 is still lacking. This study aimed to systematically delineate the oncogenic and prognostic relevance of SLC39A6 across multiple cancer types, to unravel its interplay with immune-infiltration patterns in the tumor micro-environment, and to preliminarily identify SLC39A6-associated therapeutic vulnerabilities.
methodsSLC39A6 expression profiles were retrieved from The Cancer Genome Atlas (TCGA) and cross-validated with GTEx, TIMER, HPA, cBioPortal, GEPIA2, STRING, KEGG, GO and other public repositories. Pan-cancer analyses were performed to characterize expression patterns, prognostic value, mutational landscape and functional networks. We further interrogated correlations between SLC39A6 and immune infiltration, tumor mutational burden (TMB), microsatellite instability (MSI) and immune-regulatory genes. Drug-sensitivity associations were evaluated using the CellMiner database, which facilitated molecular docking to predict binding poses and subsequent in vivo validation of lead compounds.
resultsSLC39A6 exhibited marked dysregulation across diverse tumor types and was significantly linked to patient survival. High SLC39A6 expression is associated with reduced overall survival and progression-free survival, particularly in cervical squamous cell carcinoma (CESC), as evidenced by studies that have analyzed the gene's expression and its impact on patient survival. Immune deconvolution revealed robust associations between SLC39A6 levels and the abundance of cytotoxic T cells, dendritic cells, macrophages and other immune subsets. CellMiner analyses demonstrated that increased levels of SLC39A6 resulted in enhanced sensitivity to the PI3Kα inhibitor CH5132799. Molecular docking studies predicted a strong affinity between CH5132799 and the zinc-binding pocket of SLC39A6, while mouse xenograft models further validated that CH5132799 effectively inhibited SLC39A6-mediated tumor growth.
conclusionSLC39A6 regulates the dynamics of immune infiltration and impacts prognosis in a wide range of malignancies. It emerges as a promising biomarker for prognosis, immunology, and therapy in the field of precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.